Ian M Silverman
Ian M Silverman
Repare Therapeutics
Verified email at - Homepage
Cited by
Cited by
Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle
DW Frederick, E Loro, L Liu, A Davila, K Chellappa, IM Silverman, ...
Cell metabolism 24 (2), 269-282, 2016
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
IM Silverman, A Hollebecque, L Friboulet, S Owens, RC Newton, H Zhen, ...
Cancer discovery 11 (2), 326-339, 2021
HAMR: high-throughput annotation of modified ribonucleotides
P Ryvkin, YY Leung, IM Silverman, M Childress, O Valladares, I Dragomir, ...
Rna 19 (12), 1684-1692, 2013
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
V Subbiah, NO Iannotti, M Gutierrez, DC Smith, L Féliz, CF Lihou, C Tian, ...
Annals of Oncology 33 (5), 522-533, 2022
Global analysis of the RNA-protein interaction and RNA secondary structure landscapes of the Arabidopsis nucleus
SJ Gosai, SW Foley, D Wang, IM Silverman, N Selamoglu, ADL Nelson, ...
Molecular cell 57 (2), 376-388, 2015
Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas
TA Juratli, C Thiede, MVA Koerner, SS Tummala, D Daubner, ...
Oncotarget 8 (65), 109228, 2017
RNase-mediated protein footprint sequencing reveals protein-binding sites throughout the human transcriptome
IM Silverman, F Li, A Alexander, L Goff, C Trapnell, JL Rinn, BD Gregory
Genome biology 15, 1-16, 2014
DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome
TA Juratli, D McCabe, N Nayyar, EA Williams, IM Silverman, SS Tummala, ...
Acta neuropathologica 136, 779-792, 2018
Evaluating the impact of sequencing depth on transcriptome profiling in human adipose
Y Liu, JF Ferguson, C Xue, IM Silverman, B Gregory, MP Reilly, M Li
PLoS One 8 (6), e66883, 2013
Tissue-specific RNA-Seq in human evoked inflammation identifies blood and adipose LincRNA signatures of cardiometabolic diseases
Y Liu, JF Ferguson, C Xue, RL Ballantyne, IM Silverman, SJ Gosai, ...
Arteriosclerosis, thrombosis, and vascular biology 34 (4), 902-912, 2014
The poly (C) binding protein Pcbp2 and its retrotransposed derivative Pcbp1 are independently essential to mouse development
LR Ghanem, A Kromer, IM Silverman, P Chatterji, E Traxler, ...
Molecular and cellular biology, 2016
Cytoplasmic poly (A) binding protein-1 binds to genomically encoded sequences within mammalian mRNAs
HK Kini, IM Silverman, X Ji, BD Gregory, SA Liebhaber
rna 22, 61-74, 2015
Genomic era analyses of RNA secondary structure and RNA-binding proteins reveal their significance to post-transcriptional regulation in plants
IM Silverman, F Li, BD Gregory
Plant Science 205, 55-62, 2013
Impact of poly(A)-tail G-content on Arabidopsis PAB binding and their role in enhancing translational efficiency
T Zhao, Q Huan, J Sun, C Liu, X Hou, X Yu, IM Silverman, Y Zhang, ...
Genome biology 20, 1-12, 2019
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
D Zingg, J Bhin, J Yemelyanenko, SM Kas, F Rolfs, C Lutz, JK Lee, ...
Nature 608 (7923), 609-617, 2022
Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
KM Smith, PC Fagan, E Pomari, G Germano, C Frasson, C Walsh, ...
Molecular Cancer Therapeutics 17 (2), 455-463, 2018
Chemical modifications mark alternatively spliced and uncapped messenger RNAs in Arabidopsis
LE Vandivier, R Campos, PP Kuksa, IM Silverman, LS Wang, BD Gregory
The Plant Cell 27 (11), 3024-3037, 2015
Terpene metabolic engineering via nuclear or chloroplast genomes profoundly and globally impacts off‐target pathways through metabolite signalling
EK Pasoreck, J Su, IM Silverman, SJ Gosai, BD Gregory, JS Yuan, ...
Plant biotechnology journal 14 (9), 1862-1875, 2016
Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.
IM Silverman, K Murugesan, CF Lihou, L Féliz, GM Frampton, RC Newton, ...
Journal of Clinical Oncology 37 (15_suppl), 4080-4080, 2019
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
TA Yap, E Fontana, EK Lee, DR Spigel, M Højgaard, S Lheureux, ...
Nature medicine 29 (6), 1400-1411, 2023
The system can't perform the operation now. Try again later.
Articles 1–20